Skip to main content
GUANGDONG JIAYING PHARMACEUTICAL CO., LTD. logo

GUANGDONG JIAYING PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 002198 ISIN · CNE1000008P1 LEI · 300300VXTYTBDHSI9O14 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002198

About GUANGDONG JIAYING PHARMACEUTICAL CO., LTD.

https://gdjyzy.com.cn

Guangdong Jiaying Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of Chinese patent medicines. The company focuses on the modernization of traditional Chinese medicine (TCM) through advanced pharmaceutical technologies. Its product portfolio encompasses a wide range of therapeutic areas, including respiratory health, cardiovascular diseases, digestive disorders, and anti-inflammatory treatments. Notable products include Shuangliao Houfeng San and other proprietary formulations designed for throat and oral health. The company operates large-scale production facilities compliant with Good Manufacturing Practice (GMP) standards, ensuring high-quality control across its supply chain. By integrating traditional herbal knowledge with modern clinical research, the company provides standardized healthcare solutions to diverse markets.

Recent filings

Filing Released Lang Actions
湖南启元律师事务所关于广东嘉应制药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion (“法律意见书”) issued by a law firm regarding the convening procedures, attendance qualifications, voting procedures, and voting results of the company’s 2025 Annual General Meeting. It does not itself present a financial report or management commentary, nor is it an AGM presentation or investor call transcript. Instead, it is an attestation by external counsel confirming the legality of the meeting and vote results, which falls under officer certification or attestation filings. Therefore, this letter is best classified as a general regulatory filing.
2026-05-21 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement of the 2025 annual general meeting (AGM) resolutions of Guangdong Jiaying Pharmaceutical Co., Ltd., detailing attendance, each proposal title, voting results (agree/disagree/abstain), and legal opinions. It is clearly a declaration of voting results at a shareholders meeting rather than a financial report, management commentary, or presentation. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Chinese
关于股票交易异常波动的公告
Regulatory Filings
2026-05-07 Chinese
2026年第一次临时股东会会议资料
AGM Information Classification · 100% confidence The document is titled '2026 年第一次临时股东会会议资料' which translates to '2026 First Extraordinary General Meeting (EGM) Materials'. It contains detailed information about the meeting agenda, proposals to be voted on, voting procedures, and proxy forms. The content is focused on the materials provided for the shareholders to review before the meeting, including proposals on credit limits, guarantees, and remuneration system revisions. There is no financial data or results reported, nor is it a transcript or announcement of voting results. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is over 6000 characters, indicating it is the actual meeting materials, not just an announcement. Therefore, the correct classification is AGM Information (AGM-R).
2026-03-26 Chinese
《董事、高级管理人员薪酬管理制度》（2026年3月修订）
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and mechanisms of remuneration for the company's board members and senior executives. It includes sections on salary composition, performance pay, incentive schemes, and adjustment criteria. There is no indication that this is an announcement or a brief summary; rather, it is a detailed policy document on remuneration. This matches the definition of a Remuneration Information report (DEF 14A), which covers compensation details for top executives and directors. The document length is 2410 characters, which is reasonable for such a policy document. Therefore, the appropriate classification is DEF 14A with high confidence.
2026-03-16 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for convening the 2026 first extraordinary general meeting (临时股东会) of Guangdong Jiaying Pharmaceutical Co., Ltd. It includes details about the meeting time, location, voting procedures, proposal codes, and proxy forms. It does not contain financial statements or results but is an announcement about the meeting and voting process. The document length is 3428 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2026-03-16 Chinese

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.